Lower Real-World Risk of Cardiovascular Events With Semaglutide 2.4 mg in People with Risk Factors for Atherosclerotic Cardiovascular Disease: Results from SCORE – Primary Prevention Population study
Authors:
Victoria Divino1; Zhenxiang Zhao1; Kim G. Smolderen2,3; Carlos Mena-Hurtado2; Yan Chen4; Joanna Boland4; Jinlin Song4; Briain O Hartaigh1; B. Gabriel Smolarz1; Filip K. Knop5; Michael G. Nanna2